MADRID   8-9 JUNE 2018

SPANISH HIV CLINICAL FORUM

THE SPANISH HIV CLINICAL FORUM: INTEGRASE INHIBITORS IS COMING TO MADRID ON 8-9 JUNE 2018!

 

The meeting will include plenary lectures in Spanish and English and plenty of opportunity to interact with key experts in the field during Q&A and discussions!

 

This state-of-the-art program provides challenging plenary lectures followed by ample time for Q&A and debate, stimulating interaction and bridging the knowledge  gap between experts and the HIV treating community in Spain.  Additionally, the program includes parallel skills building sessions followed  by a session where the medical community shares their clinical experience by presenting and discussing  clinical cases.

Access the meeting proceedings of the 

HAVE A LOOK AT THE PREVIOUS MEETING'S PRESENTATIONS AND CONTENT HERE:

 
 
BACKGROUND

 

The HIV CLINICAL FORUM is developed  as part of a series of interactive programs that provide independent  medical education on emerging topics in HIV. The program features International and regions experts in order to provide HIV clinicians and allied healthcare professionals with updates on the latest developments related to HIV management, providing opportunities for sharing of clinical experience and presenting results from ongoing and completed cohorts / research programs.

 

Furthermore, the HIV CLINICAL FORUM encourages skills building for optimal interpretation of research results, developing  collaborations and initiating research projects.

 
ORGANIZING COMMITTEE
Mauro Schechter, MD, PhD Federal University of Rio De Janeiro, Brazil
Mauro Schechter, MD, PhD Federal University of Rio De Janeiro, Brazil

Charles Boucher
MD, PhD

Erasmus Medical Center,

The Netherlands

Jonathan Schapiro
MD

Sheba Medical Center,

Israel

Jose Arribas
MD

Hospital La Paz,

Spain

Juan Berenguer
MD

Hospital General

Gregorio Marañón,

Spain

Josep M. Llibre
MD, PhD

Hospital Universitari Germans Trias i Pujol, Spain

Register for the

Spanish HIV Clinical Forum

Madrid | 8-9 June 2018

SCIENTIFIC COMMITTEE
Mauro Schechter, MD, PhD Federal University of Rio De Janeiro, Brazil
 
PROGRAM

FRIDAY 8 JUNE

12:30      Registration, Reception, Coffee

14:00      Welcome, Introduction and Goals

14:10      State of the ART: Integrase Inhibitors Clinical Data

               Juan Berenguer, MD – Hospital General Gregorio Marañón, Madrid

14:30      Discussion

14:40      State of the ART: Integrase Inhibitors Resistance (an update)

               Jonathan Schapiro, MD – Sheba Medical Center, Israel

15:00      Discussion

                Abstract driven presentations

15:15      Integrase inhibitors and virological failure: a cohort analysis

               Montejano, Rocio. Hospital Universitario La Paz, Madrid

15:25      Análisis descriptivo de mutaciones asociadas a resistencia (MR) para

               inhibidores de la integrasa (INI) del VIH en el Hospital Universitario de La

               Princesa de Madrid

               García-Fraile Fraile, Lucio Jesús. Hospital Universitario De La Princesa,

               Madrid

 

O_#01

O_#02

15:35      Coffee break 

Session 2  -  Changing the paradigm: Reduced drug regimens 

16:00      What is the Virological support for reduced drug regimens?

               Josep M. Llibre, MD, PhD - Hospital Universitari Germans Trias i Pujol, Barcelona

16:20      What is the Pharmacological support for reduced drug regimens?

               Esteban Ribera, MD, PhD - Hospital Universitari Vall d'Hebron, Barcelona

16:45      What are the Clinical data for reduced drug regimens?

               Babafemi O. Taiwo, MBBS - Northwestern University, USA

17:15      Discussion

                Abstract driven presentations

17:30      Comparative clinical experience with the two STR co-formulations with

               integrase inhibitors for the treatment of HIV patients

               Hernández García, Guiomar. Hospital Universitario Príncipe De Asturias,

               Alcalá De Henares

17.40      Eficacia y tolerabilidad del tratamiento con Elvitegravir, Cobicistat,

               Emtricitabina y Tenofovir Alafenamida (EVG/COBI/FTC/TAF) en

               pacientes con infección por VIH. Análisis a 24 semanas
               Bautista, Azucena. Hospital De La Princesa, Madrid

17.50      Biterapias basadas en Dolutegravir: ¿son una realidad y una necesidad

               en la práctica clínica diaria?
               Ferrer, Ana. Hospital Clínico Universitario, Valencia

18.00      Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-

               infected patients: 48-week results of the KIRAL study
               Troya, Jésus. Hospital Universitario Infanta Leonor, Madrid

 

O_#03

O_#04

O_#05

O_#06

18:10      Discussion

18:20      Welcome reception

19:30      Networking Dinner

SATURDAY 9 JUNE

Session 3  -  Integrase Inhibitors in Routine Care

09:00      Optimizing Clinical Care

               José Arribas, MD - Hospital Universitario La Paz, Madrid

09:20      Optimal Clinical Care in special populations

               Matilde Sánchez Conde, MD - Hospital Universitario Ramón y Cajal, Madrid

09:45      Discussion

                Abstract driven presentation

09:55      Interstitial pneumonia by triple viral co-infection in a CDC C2 HIV-

               infected patient
               Bracke, Carme. Hospital Germans Trias I Pujol, Badalona

 

O_#03

10:05      Clinical Case presentation

               Antonio Antela, MD - Hospital Clínico Universitario de Santiago de Compostela, A Coruña

10:30      Discussion

10:45      Coffee break 

Session 4  -  Novel delivery systems

11:15      Integrating novel delivery systems/novel drugs

               Maria Luisa Montes, MD, PhD - Hospital Universitario La Paz, Madrid

11:45      Discussion

12:00      Closing Remarks

12:10      End of Meeting

13:00      Lunch

Session 1  -  State of the Art Update  -  Integrase Inhibitors

 
 
ABSTRACTS

Are you doing research on one of the topics below and have data that you would like to share and/or discuss with your colleagues? Then we encourage you to submit your abstract!

 

Please note that those with accepted abstract will be offered a CPG (guaranteed).

Abstract topics:
•    Basic Virology
•    Resistance
•    Pharmacology and Drug interactions
•    Toxicity
•    Reduced Drug Regimens
•    Clinical Trials
•    Informative case reports

 

ABSTRACT SUBMISSION IS NOW OPEN

General guidelines
Abstracts should contain the following four components (please bold the four section headings noted below within the text of your abstract submission):

 

Background: a concise statement of the issue under investigation or a hypothesis;
Materials & Methods: the experimental methods used (including the statistical analyses employed);
Results: specific findings (promises such as "to be completed" or "to be presented" are not acceptable);
Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables, graphs, grant acknowledgements or literature references are included. We advise you to keep a word count for the abstract body to a maximum of 500 words.


Abstracts are considered official communications to the conference and will be treated confidentially.
 

Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.

To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Categories for abstract submission
For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

 

Notification of abstract acceptance and presentation format
Notifications of acceptance and format of presentation (oral or poster presentation) will be e-mailed to submitting authors before 11 May 2018. It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status.

Please notify the Conference Secretariat if you have not received notification by 14 May 2018.

If an abstract is accepted, one author is required to register for the conference and present the paper as scheduled.

Abstract Submitter’s Registration Guidelines will be sent together with the notification. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.

Abstract publication
Accepted abstracts will be published in the Conference Abstract Book, which will be distributed during the conference. In addition, all abstracts will be published in the journal "Reviews in Antiviral Therapy & Infectious Diseases". Please note that the Conference Secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.

Submit your abstract for the

Spanish HIV Clinical Forum

The extended deadline

for abstract submissions is:

11 May 2018

REGISTRATION FEES

 

Registration is free of charge for all healthcare practitioners*. A registration fee applies to other individuals.


*Healthcare practitioners are defined as professionals that provide any type of health care service to patients living with HIV. If you are not sure, please do not hesitate to contact us at info@virology-education.com.

 

CONFERENCE PARTICIPATION GRANTS (CPG)

EXTENDED deadline: Friday 11 May 2018

Virology Education (VE), with generous support by Laboratorios ViiV Healthcare is offering Conference Participation Grants (CPGs) for the Spanish HIV Clinical Forum to HIV healthcare professionals from Spain.

What the CPG covers
  1. Support for air/train travel of up to EUR 300

  2. Hotel accommodation for 1 night on Friday 8 June 2018

PLEASE NOTE: 
a)    All arrangements will be made by Virology Education
b)    Applicants must attend the entire Conference.
c)    Applicants will be responsible for all other costs associated with Conference attendance. 
d)    Please see the Conference website for further details about the Conference. 

What is expected from you:
  1. Recipient will be onsite at the Conference, attend all sessions and participate actively for the duration of the Conference. Recipient must sign in to each session as requested by VE. 

  2. Recipient will  provide a post-meeting feedback and summary about his/her Conference experience within  1 month after the end of the Conference. The feedback questionnaire will be an online survey with the recipient providing feedback on their experience at the conference, CPG procedure and how they will implement the knowledge acquired at the meeting in their daily practice. The questionnaire will be send to each recipient by email within one week after the conclusion of the conference.

Eligibility:
  1. The applicant must be a Healthcare Professional.

  2. The applicant must be willing to share his/her experience at the Conference within his network.

  3. The applicant must be eligible to obtain a visa for travel.

  4. The applicant must declare that she/he is able and willing to fund all other costs beyond the grant that are involved in attending the Conference, e.g. all other hotel, travel and subsistence expenses NOT covered by the CPG.

  5. The applicant must declare to take out her/his own insurance policies (for travel, liability, illness and/or other necessary insurances in relation to her/his participation to the Conference).

.

Application procedure:
  1. Your application will include the following:

  • Your contact details (e.g. name and email address)

  • CV

  • Motivation letter consisting of a written statement of up to 200 words, on

    • how attending the Conference will benefit you in a professional capacity

    • how you intend to apply the benefits that you have outlined in a practical way after the Conference

  • Recommendation letter(s) (optional)

  • Abstract(s) (optional)

  • A declaration that you agree with the terms & conditions for application

  1. Your application must be received by 11 May 2018.

  2. All applications will be acknowledged upon receipt.

  3. All applications will be reviewed by an independent CPG Review Committee based on the following Grant Selection Criteria:

    • Professional background

    • Strategy of knowledge dissemination

    • Recommendation by the Scientific and Organizing Committee of the meeting

    • Quality of the Abstract (if accepted)

    • Young/ Early Career Investigator

  4. All applicants will receive notification of the application status no later than 25 May 2018.

.

Please submit your application through the CPG Application Portal on the Conference website.  

We humbly request your support in encouraging healthcare professionals to apply by forwarding this information to your colleagues.

SPONSOR

This educational activity is supported by an educational grant from Laboratorios ViiV Healthcare.

 

ENDORSERS

*

*The opinions of the speakers do not necessarily reflect GeSIDA's stances

 
PRACTICAL INFORMATION

 

Practical Information

We trust that the following information (in alphabetical order) will assist you in organizing your registration and stay in Spain.

Accommodation

The accommodation information will be coming soon.

 

Badges

All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.

 

Certificate of Attendance

A certificate of attendance will be sent by e-mail after the workshop.

 

Conference materials

Conference materials can be obtained upon registration at the registration desk at the Conference Venue starting 12.30 PM

on Friday 8 June.

 

Conference language

The official conference language is Spanish and English.

 

Disclaimer

This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.

 

Liability and insurance

By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.

 

Meeting venue

The meeting will be held at Ayre Gran Hotel Colón, a 4-star designer hotel located in the center of Madrid, and very close to the Retiro Park, the Las Ventas Bull Ring and the Salamanca commercial district. (Source: http://www.ayrehoteles.com/hoteles/ayre-gran-hotel-colon/)

Ayre Gran Hotel Colón

C/ del Pez Volador, 1

28007 Madrid

T: +34 91 4009900

E: reservas.colon@ayrehoteles.com

W: http://www.ayrehoteles.com/hoteles/ayre-gran-hotel-colon/

 

Internet access

Free WIFI will be available in the meeting room. Access codes will be made available on the first day of the meeting.

Payment and procedure of on-line registration

Registration is free of charge for all healthcare practitioners. Your registration will be confirmed as soon as possible. If you do not receive a confirmation within three days after your registration, please contact the organizing secretariat email: info@virology-education.com.

 

Photographs, audio and video recording

Photographs as well as audio and video recordings are not permitted at the official meeting sessions. Only the official medical writer, appointed by the organization, may make recordings. All presentations, will be posted on the workshop website (under Workshop Materials) as soon as possible after the workshop is finished, provided the speaker has given permission to do so.

 

Contact

Inquiries

For any inquiries or questions, please contact Virology Education at info@virology-education.com or call +31 (0)30 230 7140. You can also contact us by filling out the contact form.

Lena Hartandi-Niesen

Project Manager

lena@vironet.com

Naima Calor

Project Manager

naima@vironet.com

Contact form

Conference materials:

infectiousdiseasesonline.com

© 2020 By Virology Education